Bioregulator Research

Vilon

6.4/10

BioHarmony verdict

Worth trying

Vilon is the Lysine-Glutamic acid (KE) dipeptide from Vladimir Khavinson's bioregulator program, sold for immune restoration and anti-aging. The cell and animal data are real but come entirely from one lab, with zero independent replication and zero registered trials, per the single-source record summarized in Khavinson 2013.

Read full report

What is Vilon?

Vilon is a lab-made dipeptide, just two amino acids, Lysine and Glutamic acid, stuck together. In peptide circles it goes by the shorthand "KE," and it comes out of Vladimir Khavinson's bioregulator program in St. Petersburg. It is marketed for immune restoration and general anti-aging, and the proposed idea is that this tiny peptide slips into cells and interacts directly with your DNA to nudge gene expression, layered on a thymus and immune-restoring action, per Khavinson 2023.

From the BioHarmony report, reviewed 2026-09-08.

Safety watch-outs

  • Any active or suspected cancer: do not use
  • immune and neuroendocrine experimentation is unwise there.
  • Pregnancy or breastfeeding: do not use
  • there is no human safety data.
  • Injection-site infection, fever, or systemic reaction (possible contaminated grey-market material): stop immediately and seek care.

Full risk profile in the BioHarmony report.

Dosing as published

No approved-label or study protocol is recorded for Vilon yet.

More reported protocols

Members

Members can compare additional reported doses, schedules, and preparation notes.

Educator coverage (2)

Attributed viewpoints, separate from primary research.

Trust & sourcing

US approvalNot FDA approved
CompoundingNo FDA-approved U.S. product is identified in the reviewed source set
Last checked2026-07-13
Next review2027-01-09

Vilon is a synthetic dipeptide studied in cell and animal models. The reviewed human and rat thymic-cell study does not establish clinical safety or effectiveness in people.

Primary sources

Free guide

The Ultimate Peptides Guide

Spot stronger candidates, weak evidence, and seller red flags before you buy.

Free. Includes evidence and regulatory updates. Unsubscribe anytime.